MSS

19 registered clinical trials studyying MSS — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors NCT07001592	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	Phase 1
Recruiting	SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases NCT06850103	First Affiliated Hospital of Zhejiang University	Phase 2
Recruiting	SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer NCT06908031	Sixth Affiliated Hospital, Sun Yat-sen University	Phase 2
Not Yet Recruiting	Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Col NCT06593548	Fudan University	Phase 2
Not Yet Recruiting	Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab NCT06415851	Zhangfa Song	Phase 2
Recruiting	ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC NCT06321081	Beijing Hospital	Phase 2
Active Not Recruiting	Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment NCT06199232	Peking University	N/A
Unknown	Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer NCT05933980	Sun Yat-sen University	Phase 2
Recruiting	Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk NCT05877573	Nanfang Hospital, Southern Medical University	N/A
Terminated	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC NCT05733611	Replimune, Inc.	Phase 2
Unknown	XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer NCT05815303	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Recruiting	Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer NCT05731726	Zhejiang University	Phase 2
Unknown	Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atez NCT04659382	Federation Francophone de Cancerologie Digestive	Phase 2
Unknown	QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer NCT04527068	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
Unknown	Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mism NCT04483219	China Medical University, China	Phase 2
Active Not Recruiting	Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer NCT04046445	Amal Therapeutics	Phase 1
Unknown	Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer NCT04030260	Sun Yat-sen University	Phase 2
Completed	Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC NCT03274804	University Hospital Heidelberg	Phase 1
Completed	Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-s NCT03271047	Pfizer	Phase 2